Companies
Biogen
pioneering complex biologic therapeutics targeting neurodegenerative diseases like Alzheimer's.
- Country
- United States
- Ticker
- BIIB
neurology
us
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Headquarters | Cambridge, Massachusetts, United States | umbrex.com |
| Production site | Research Triangle Park (Wake and Durham counties), North Carolina, United States | investors.biogen.com · biogen.com |
| Production site | Solothurn, Switzerland | investors.biogen.com · biogen.com · bioprocessintl.com |
| Capacity | 263,000 liters of installed bioreactor capacity | biogen.com |
| Certification | Good Manufacturing Practice (GMP) multi-product license for Solothurn facility | investors.biogen.com · bioprocessintl.com |
| Funding | $200 million received in 2025 from Royalty Pharma with up to $50 million in 2026 for litifilimab development funding | sec.gov |
Independent sources: bioprocessintl.com · sec.gov · umbrex.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biopharmaceuticals & biomedicines | therapeutics-platforms | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.